Changeflow GovPing Healthcare & Life Sciences PEMF Therapy in Shoulder Tendinopathy - NCT0755...
Routine Notice Added Final

PEMF Therapy in Shoulder Tendinopathy - NCT07550543

Favicon for changeflow.com ClinicalTrials.gov Studies
Published
Detected
Email

Summary

This ClinicalTrials.gov registry entry documents a randomized controlled trial evaluating whether pulsed electromagnetic field (PEMF) therapy via the Super Inductive System (SIS), added to a multimodal rehabilitation program, improves pain, function, pressure pain threshold, muscle strength, psychological status, and quality of life in adults with shoulder tendinopathies. The study will compare participants receiving standard balneophysiotherapy against those receiving the same treatment supplemented with PEMF (SIS) therapy. Evaluations occur at baseline, discharge, and 4 weeks post-treatment using validated clinical instruments.

“The goal of this clinical trial is to evaluate whether pulsed electromagnetic field (PEMF) therapy delivered via the Super Inductive System (SIS), integrated into a multimodal rehabilitation program, improves pain, function, pressure pain threshold, muscle strength, psychological status, and quality of life in adults with shoulder tendinopathies.”

NIH , verbatim from source
Published by NIH on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.

What changed

This is a new clinical trial registry entry on ClinicalTrials.gov describing a randomized controlled trial investigating the efficacy of PEMF (SIS) therapy as an adjunct to multimodal rehabilitation for shoulder tendinopathies. The trial enrolls adults with shoulder tendinopathy and randomizes them to receive either standard balneophysiotherapy or the same treatment supplemented with PEMF (SIS) therapy.

Healthcare providers and clinical researchers should note that this trial examines a specific electromagnetic field intervention (Super Inductive System) in combination with balneophysiotherapy, with primary endpoints including pain intensity and pressure pain threshold, and secondary endpoints covering function, muscle strength, psychological status, and quality of life. The study uses validated clinical instruments at three time points: baseline, discharge, and 4-week follow-up.

Archived snapshot

Apr 24, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← ClinicalTrials.gov Studies

PEMF Therapy in Shoulder Tendinopathy

N/A NCT07550543 Kind: NA Apr 24, 2026

Abstract

The goal of this clinical trial is to evaluate whether pulsed electromagnetic field (PEMF) therapy delivered via the Super Inductive System (SIS), integrated into a multimodal rehabilitation program, improves pain, function, pressure pain threshold, muscle strength, psychological status, and quality of life in adults with shoulder tendinopathies.

The main questions it aims to answer are:

  • Does the addition of PEMF (SIS) therapy reduce pain intensity and improve pressure pain threshold compared to standard balneophysiotherapy?
  • Does PEMF (SIS) therapy improve shoulder function, muscle strength, psychological status, and quality of life? The study will compare a multimodal rehabilitation program supplemented with PEMF (SIS) therapy to standard balneophysiotherapy to determine whether the addition of PEMF (SIS) provides superior clinical outcomes.

Participants will:

  • Undergo a multimodal rehabilitation program including balneophysiotherapy
  • Be assigned to receive either standard treatment or treatment supplemented with PEMF (SIS) therapy
  • Be evaluated at baseline (admission), immediately after treatment completion (discharge), and at 4 weeks after treatment using validated clinical instruments assessing pain, function, pressure pain threshold, muscle strength, psychological status, depressive symptoms, and quality of life.

Conditions: Shoulder Tendinopathy

Interventions: Nanopulsed Electromagnetic Field Therapy (SIS), Balneophysiotherapy

View original document →

Get daily alerts for ClinicalTrials.gov Studies

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from NIH.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
NIH
Published
April 24th, 2026
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Healthcare providers Clinical investigators Patients
Industry sector
6211 Healthcare Providers
Activity scope
Clinical trial registration Medical device research Rehabilitation therapy
Geographic scope
United States US

Taxonomy

Primary area
Healthcare
Operational domain
Clinical Operations
Topics
Medical Devices Pharmaceuticals Public Health

Get alerts for this source

We'll email you when ClinicalTrials.gov Studies publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!